Open Access

Association between MDR1 polymorphisms and XELIRI and XELOX chemoresistance in Saudi patients with colorectal cancer

  • Authors:
    • Ayat B. Al‑Ghafari
    • Areej M. Al Qahtani
    • Suzan N. Alturki
    • Huda A. Al Doghaither
    • Ekramy M. Elmorsy
    • Hanaa M. Tashkandi
    • Atlal M. Abusanad
    • Shadi S. Alkhayyat
    • Ulfat M. Omar
    • Ahmed A. Zeeneldin
  • View Affiliations

  • Published online on: August 24, 2020     https://doi.org/10.3892/ol.2020.12016
  • Article Number: 155
  • Copyright: © Al‑Ghafari et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Multidrug resistance member 1 (MDR1) is located on chromosome 7 and encodes P‑glycoprotein, which is universally accepted as a drug resistance biomarker. MDR1 polymorphisms can alter protein expression or function, which has been previously reported to associate with various types of malignancies, such as colorectal cancer (CRC). Therefore, the present study aimed to determine the effects of MDR1 polymorphisms on drug responses of Saudi patients with CRC. DNA samples were obtained from 62 patients with CRC and 100 healthy controls. Genotypes and allele frequencies of MDR1 single nucleotide polymorphisms (SNPs) G2677T and T1236C were determined using the PCR‑restriction fragment length polymorphism procedure. The results showed no significant differences in the genotype distribution and allele frequency of T1236C between patients with CRC and controls. However, G2677T was found to serve a highly significant role in protecting against the progression of CRC. In addition, none of the genotypes in SNPs T1236C and G2677T was found to affect chemoresistance to XELIRI and XELOX. In conclusion, although T1236C in the MDR1 gene is not associated with CRC risk, G2677T protects against the development of CRC. Neither of the MDR1 SNPs tested were associated with the risk of chemoresistance. Therefore, these two SNPs cannot be used as molecular markers for predicting drug response in patients with CRC.
View References

Related Articles

Journal Cover

November-2020
Volume 20 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Al‑Ghafari AB, Al Qahtani AM, Alturki SN, Al Doghaither HA, Elmorsy EM, Tashkandi HM, Abusanad AM, Alkhayyat SS, Omar UM, Zeeneldin AA, Zeeneldin AA, et al: Association between <em>MDR1</em> polymorphisms and XELIRI and XELOX chemoresistance in Saudi patients with colorectal cancer. Oncol Lett 20: 155, 2020
APA
Al‑Ghafari, A.B., Al Qahtani, A.M., Alturki, S.N., Al Doghaither, H.A., Elmorsy, E.M., Tashkandi, H.M. ... Zeeneldin, A.A. (2020). Association between <em>MDR1</em> polymorphisms and XELIRI and XELOX chemoresistance in Saudi patients with colorectal cancer. Oncology Letters, 20, 155. https://doi.org/10.3892/ol.2020.12016
MLA
Al‑Ghafari, A. B., Al Qahtani, A. M., Alturki, S. N., Al Doghaither, H. A., Elmorsy, E. M., Tashkandi, H. M., Abusanad, A. M., Alkhayyat, S. S., Omar, U. M., Zeeneldin, A. A."Association between <em>MDR1</em> polymorphisms and XELIRI and XELOX chemoresistance in Saudi patients with colorectal cancer". Oncology Letters 20.5 (2020): 155.
Chicago
Al‑Ghafari, A. B., Al Qahtani, A. M., Alturki, S. N., Al Doghaither, H. A., Elmorsy, E. M., Tashkandi, H. M., Abusanad, A. M., Alkhayyat, S. S., Omar, U. M., Zeeneldin, A. A."Association between <em>MDR1</em> polymorphisms and XELIRI and XELOX chemoresistance in Saudi patients with colorectal cancer". Oncology Letters 20, no. 5 (2020): 155. https://doi.org/10.3892/ol.2020.12016